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Abstract: Parkinson’s Disease (PD) is characterized by the massive loss of dopaminergic neurons,
leading to the appearance of several motor impairments. Current pharmacological treatments, such as
the use of levodopa, are yet unable to cure the disease. Therefore, there is a need for novel strategies,
particularly those that can combine in an integrated manner neuroprotection and neuroregeneration
properties. In vitro and in vivo models have recently revealed that the secretome of mesenchymal
stem cells (MSCs) holds a promising potential for treating PD, given its effects on neural survival,
proliferation, differentiation. In the present study, we aimed to access the impact of human bone
marrow MSCs (hBM-MSCs) secretome in 6-hydroxydopamine (6-OHDA) PD model when compared
to levodopa administration, by addressing animals’ motor performance, and substantia nigra (SN),
and striatum (STR) histological parameters by tyrosine hydroxylase (TH) expression. Results revealed
that hBM-MSCs secretome per se appears to be a modulator of the dopaminergic system, enhancing
TH-positive cells expression (e.g., dopaminergic neurons) and terminals both in the SN and STR when
compared to the untreated group 6-OHDA. Such finding was positively correlated with a significant
amelioration of the motor outcomes of 6-OHDA PD animals (assessed by the staircase test). Thus,
the present findings support hBM-MSCs secretome administration as a potential therapeutic tool in
treating PD, and although we suggest candidate molecules (Trx1, SEMA7A, UCHL1, PEDF, BDNF,
Clusterin, SDF-1, CypA, CypB, Cys C, VEGF, DJ-1, Gal-1, GDNF, CDH2, IL-6, HSP27, PRDX1, UBE3A,
MMP-2, and GDN) and possible mechanisms of hBM-MSCs secretome-mediated effects, further
detailed studies are needed to carefully and clearly define which players may be responsible for its
therapeutic actions. By doing so, it will be reasonable to presume that potential treatments that can,
per se, or in combination modulate or slow PD may lead to a rational design of new therapeutic or
adjuvant strategies for its functional modeling and repair.
Keywords: Parkinson’s Disease; mesenchymal stem cells; stem cells secretome; levodopa
1. Introduction
Parkinson’s Disease (PD) represents the second most prevalent (worldwide) neurodegenerative
disorder and is characterized by the progressive degeneration of dopaminergic neurons (DAn) in
several dopaminergic networks [1]. As a consequence, patients develop several motor complications
including rigidity, bradykinesia, and tremors [2]. Mitochondrial dysfunction, excessive reactive
oxygen species (ROS), and ubiquitin-proteasome (UPS) impairment have been consistently described
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as involved in the mechanisms responsible for DAn degeneration [3]. The loss of dopamine (DA),
irrespectively of the causal chain of events, underlies the reasoning for the gold standard treatment
of PD, which still is the administration of levodopa [4]. Nevertheless, although the application of
such treatment is efficient in reducing the resting-tremors and other primary motor symptoms during
the first years of the disease, it remains, however, insufficient to preserve, or replace degenerated
DAn or to stop further progression of PD [5–7]. Furthermore, its extended use, frequently associated
with an increase in dosage due to the natural progression of the disease, has been associated with
the appearance of nausea, vomiting, low blood pressure, restlessness, drowsiness or sudden onset of
sleep, as well as impulsive and addiction behavioral changes [5]. This ‘pathophysiological’ effect of
levodopa has been described as being due to a combination of disease-related factors, as well as to
levodopa pharmacokinetics itself [8]. Actually, while the correlation to disease factors remains unclear,
the unusual pharmacokinetic characteristics of levodopa, per se, have been correlated with motor
complications pathogenesis (e.g., dyskinesia’s). Indeed its (very) short half-life leads to abnormal
pulsatile stimulation of DA receptors, inhibiting the establishment of a correct and effective balance of
the nigrostriatal pathway [8]. Therefore, there is an urgent need to find novel therapeutic strategies
that can overcome the limitations posed by levodopa, not only to delay the progression of PD but also
to improve and maintain PD patients’ quality of life.
One such alternatives is cell transplantation strategies that profit from the potential regenerative
properties provided by the use of stem cells. In accordance, mesenchymal stem cells (MSCs) have
themselves been proposed as a promising therapeutic tool for PD [9] given their ability to modulate
DAn survival and differentiation [1]. Actually, MSCs have been defined as a multipotent stem
cell population with a great therapeutic potential for several diseases, being available widespread
throughout the human body by presenting a great proliferative potential with minimal senescence
through multiple passages [1]. According to the International Society for Cellular Therapy (ISCT) there
are minimal criteria to identify MSC populations such as (1) the adherence to plastic in standard culture
conditions; (2) the positive expression of specific markers like CD73, CD90, CD105, and negative
expression of hematopoietic markers like CD34, CD45, HLA-DR, CD14, or CD11B, CD79α or CD19,
as well as (3) the in vitro differentiation into at least adipocytes, osteoblasts, and chondroblasts [10].
Notwithstanding, recent evidence has claimed that these criteria do not totally support a complete
purification of homogenous MSC populations, assuming that the isolation of MSCs according to the
ISCT criteria produces heterogeneous, nonclonal cultures of stromal cells containing stem cells with
different multipotential properties, committed progenitors, and differentiated cells [11]. Therefore,
although the nature and function of pure MSCs remain to be explored, the therapeutic effects of them
under the current definition have demonstrated promising outcomes both from pre-clinical and clinical
points of view [12].
These beneficial effects have been attributed to their secretome, which has been described as a
complex mixture of soluble products composed by a proteic soluble fraction (constituted by growth
factors and cytokines), and a vesicular fraction composed by microvesicles and exosomes, which
are involved in the transference of proteins and genetic material (e.g., miRNAs) to other cells, with
promising therapeutic effects [12]. In addition to this, recent studies have indicated that rather than
being a regular mixture of molecular bioactive molecules, MSCs paracrine activity is known to be
dependent on the diverse stimuli present in the microenvironment in which MSCs are located or
delivered [13]. Being so, studies have indicated that the composition of MSCs secretome can be
modulated by preconditioning them during in vitro culture [13].
Our lab has shown that the sole injection of MSCs secretome discloses the same effects to
those observed in MSC cell-transplanted groups in the improvement of neuronal and glial densities,
thereby indicating that MSCs secretome per se can be used as a ready-to-use product for therapeutic
purposes [14]. Furthermore, we have succeeded in modulating MSCs secretome using dynamic culture
conditions through computer-controlled bioreactors [15], which when locally applied in the substantia
nigra (SN) and striatum (STR) of a 6-hydroxydopamine (6-OHDA) unilateral PD rat model, had a
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significant effect on the survival of DAn, a fact that was positively correlated with animal motor
performance amelioration [16]. This is, therefore, the right timing to address MSCs secretome as a
promising therapeutic tool in treating PD, by comparing it to levodopa. Thus, in the present work,
we addressed the impact of MSCs secretome on DAn cell survival and motor function of a 6-OHDA
animal model of PD by comparing it to levodopa administration, exploring possible mechanisms and
pathways having in mind the neuroregulatory profile of MSCs secretome.
2. Methods
2.1. Expansion of Human Bone Marrow MSCs (hBM-MSCs) and Secretome Collection
Pre-isolated and cryopreserved hBM-MSCs were thawed at 37 ◦C and plated in a T-75-treated
polystyrene flask culture with 15 mL ofα-MEM growth medium (containing 1% of antibiotic/antimycotic
and 10% of fetal bovine serum (FBS) (Invitrogen, Waltham, MA, USA). The cell culture medium was
renewed every 3 days and the culture maintained at 37 ◦C, 5% CO2, 95% air, and 90% relative humidity
until confluence. After 80–90% of cell confluence, the cells were enzymatically digested with 0.05%
trypsin for 5 min at 37 ◦C. α-MEM growth medium was used to stop the reaction. Following that,
the cells were centrifuged at 1200 rpm for 5 min, the pellet was resuspended, and 5000 cells/cm2
were plated into new cell culture flasks and the procedure was repeated until cells reached passage
5 (P5). Therefore, at P5 and for secretome collection (e.g., in the form of conditioned medium (CM),
5000 cells/cm2 were plated and kept for 3 days in α-MEM medium (Invitrogen, USA) supplemented
with 1% of antibiotic/antimycotic (Invitrogen, USA) and 10% FBS (Invitrogen, USA). After this, the
flasks were washed three times in Neurobasal A medium (Invitrogen, USA) for 5 min and then, washed
five times in PBS without Mg2+/Ca2+ (Invitrogen, USA). Neurobasal A medium supplemented with
kanamycin (1%) (Invitrogen, USA) was added and 24 h after, the medium was collected and frozen at
−80 ◦C until use.
2.2. 6-Hydroxydopamine (6-OHDA)-Induced Lesions and hBM-MSCs Secretome and Levodopa Administration
All the surgical procedures, from the establishment of the 6-OHDA PD model to the surgical
administration of hBM-MSCs secretome, were performed as we previously described [16]. Briefly,
nine-week-old Wistar Han male rats (≈300 g; Charles River, Barcelona, Spain) were housed (two per
cage) and maintained in a controlled environment at 22–24 ◦C and 55% humidity, on 12 h light/dark
cycles and fed with regular rodents’ chow and tap water ad libitum. A week prior to the beginning
of injections animals handling was performed, aiming to reduce the stress induced by the surgical
procedures. All these manipulations were done in accordance with the Portuguese National Authority
for animal experimentation, Direção Geral de Veterinária (ID: DGV28421) and the regulations on animal
care and experimentation (European Union Directive 2010/63/EU). Therefore, for 6-OHDA-induced
lesion, ketamine-medetomidine (75 mg/kg; 0.5 mg/kg, intraperitoneally (IP)) anesthesia was used,
animals (n = 35) were placed on a stereotaxic frame (Stoelting, Wood Dale, IL USA), and unilaterally
injected, using a 30-gauge needle Hamilton syringe (Hamilton, Bonaduz, CH, Switzerland), with either
vehicle (Sham group, n = 9) or 6-OHDA (Sigma, n = 26) directly into the medial forebrain bundle (MFB)
(coordinates related to Bregma: AP = −4.4 mm; ML = 1.0 mm; DV = −7.8 mm [17]; according to Paxinos
and Watson brain atlas [18]). Therefore, sham animals received 2 µL of 0.2 mg/mL of ascorbic acid
in 0.9% of NaCl and, 6-OHDA animals were injected with 2 µL of 6-OHDA hydrochloride (4 µg/µL)
with 0.2 mg/mL of ascorbic acid in 0.9% of NaCl at a rate of 1.0 µL/min. After each injection, the
needle was left in place for 4 min in order to avoid any backflow up the needle tract. Three weeks after
this procedure, a behavioral assessment using the staircase and apomorphine turning behavior was
performed to validate the model (Figure 1).
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Figure 1. Experimental design. A unilateral 6-hydroxydopamine (6-OHDA) injection into the medial
forebrain bundle (MFB) was performed to induce the rat Parkinson’s Disease (PD) model. Animal
behavioral analysis through rotameter and staircase behavioral tests was performed to validate the
model 3 weeks after 6-OHDA injections. Afterwards, human bone marrow mesenchymal stem cells
(hBM-MSCs) secretome was (5 weeks after 6-OHDA injections) locally administrated into the substantia
nigra (SN) and striatum (STR), respectively. Levodopa (LD), in turn, was given by oral gavage. 1 and 4
weeks after this treatment procedures, fine motor behavioral assessment (i.e., staircase) was performed.
Concerning treatment procedures, 5 weeks after 6-OHDA PD model induction animals received
hBM-MSCs secretome and levodopa. Therefore, 6-OHDA animals were intracranially injected with the
vehicle, namely Neurobasal®-A medium with kanamycin (6-OHDA group; n = 10), and with hBM-MSC
secretome (Secretome group; n = 8) directly in the SNc and STR as we have previously described [16].
Regarding levodopa treatment (n = 8), Sinemet® tablets (Sinemet®, 100/25 levodopa/carbidopa, Merck,
Sharp and Dohme, S.p.A, Italy) were crushed in water and given by oral gavage, 12 mg/kg and
1 h before behavioral assessment as we previously performed [19]. At 1 and 4 weeks, behavioral
assessment was performed (Figure 1).
2.3. Staircase Test
To access animals’ skilled forelimb motor function, the staircase behavioral test was performed as
we have previously described [20]. Briefly, five pellets were placed into each step/well of the double
staircase apparatus. In the first 2 days, the animals were subject to a training session, familiarizing with
the test apparatus and pellets, which were available for 5 and 10 min, on days 1 and 2, respectively.
After that, and during (test session) five consecutive days, animals were kept inside the box and
bilaterally exposed to food pellets, having 15 min to reach, retrieve, and eat those pellets present on the
steps. Finally, in the last 2 days of testing, animals were exposed to a forced-choice task (FC), having
pellets of food-restricted just to one of the steps’-sides (e.g., right (FCR) and left (FCL)). All the sessions
were performed at the same time of day and with food-restricted animals. After each test interval,
animals were removed from staircase boxes and the remaining (leftover) pellets were counted.
2.4. Apomorphine Turning Behavior
To access dopaminergic nigrostriatal integrity after 6-OHDA-induced lesions (and validate
the model), apomorphine-induced turning behavior (also known as rotameter behavioral test) was
performed. Animals’ necks were subcutaneously injected with a dopamine agonist namely through
a 0.05 mg/kg apomorphine hydrochloride (Sigma, St. Louis, MO, USA) solution dissolved in 1%
of ascorbic acid in 0.9% of NaCl as we have previously demonstrated. After this, the number
of contralateral rotations was digitally recorded, allowing the assessment of vehicle and 6-OHDA
injections. Apomorphine was just used to this purpose, and its repeated use was not provided, as it
could lead to an overstimulation of the dopaminergic system, and lead to an inadequate interpretation of
hBM-MSCs secretome and levodopa effects on the functional outcomes of 6-OHDA PD animals [21–23].
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2.5. Tyrosine Hydroxylase (TH) Immunostaining and Striatal Fiber Density Measurement
Ten weeks after the development of the 6-OHDA PD model and consequent treatment application
and behavioral analysis, animals were euthanized with a sodium pentobarbital (Eutasil, 60 mg/kg
i.p. Ceva Saúde Animal, Portugal) injection, and transcardially perfused with 4% paraformaldehyde
(Merck, Lisbon, Portugal) in 0.1 M PBS. For histological procedures and analysis, striatal and
mesencephalon coronal sections (containing SN) with 30 µm of thickness were obtained with a
vibratome (VT1000S, Leica, Germany), TH staining being performed as we previously described [16].
Briefly, and for TH-positive cell quantification on the SN, six identical TH-labeled slices spanning
the entire mesencephalon were chosen, including all the portions of the SN. Using a bright-field
microscope (BX51, Olympus, Center Valley, PA, USA) equipped with a digital camera (PixeLINK
PL-A622, CANIMPEX Enterprises Ltd., Halifax, NS, Canada), and with the help of VisiomorphTM
software (V2.12.3.0, Visiopharm, Hørsholm, Denmark), the boundaries of the SN area were drawn.
The delineation of this region was performed through the identification of anatomic standard reference
points with the help of rat brain atlas [18], and the counting of total TH-positive cells in the SN area
was performed on both hemispheres. Data is presented as the percentage (%) of remaining TH-positive
cells in the injected side, compared to the control side.
Concerning TH immunoreactive striatal fibers, the total immunoreactivity of all TH fibers was
measured by densitometry as described by Febbraro et al. [24]. Therefore, four TH-immunostained
prosencephalon sections representing the coordinates of injection sites within the striatum were selected
and photographed as we previously demonstrated [16]. Photos were converted to greyscale using
Image J program (1.51 version; National Institute of Health, Bethesda, MD, USA) and analyzed for grey
intensity after calibrating the Image J program, by accessing the optical density (O.D.) of the selected
sections and by following the program instructions. Shortly, striatum O.D. values were determined
in both brain hemispheres using a 1.1 mm2 rectangular grid, including the injection coordinates, as
determined by anatomical references and rat brain atlas [18]. Corpus callosum O.D. measurement
was also performed in both brain hemispheres, using it as an internal control to avoid nonspecific
background. Therefore, TH-positive striatal fiber densities were determined by calculating the O.D.
difference between the striatum treated with hBM-MSCs secretome, levodopa, and Neurobasal®-A
medium with the intact striatum, in which the extension of the immunostaining on the lesioned side
was expressed as a percentage of the intact side.
2.6. Statistical Analysis
Statistical evaluation for animal apomorphine behavioral test (after 6-OHDA) injection was
performed by Student’s t-test. For the staircase test, upon 6-OHDA and even hBM-MSCs secretome,
levodopa or Neurobasal®-A medium injections, ANOVA repeated measures followed by post-hoc
Bonferroni for multiple comparisons was performed using SPSS statistic program (version 25; IBM Co.,
Armonk, NY, USA). Graphical representation by using GraphPad Prism ver.8 (GraphPad Software,
La Jolla, CA, USA). Equality of variances and sphericity were measured using the Levene’s and
Mauchly’s tests, respectively, and was assumed when p > 0.05. Data are presented as mean ± SEM.
The significance value was set at p < 0.05. Effect size was calculated using η2 partial.
3. Results
3.1. 6-OHDA PD Model Phenotypic Validation
To access nigrostriatal functional integrity after 6-OHDA administration, we used the apomorphine
turning behavioral test. From the results, and 3 weeks after, we observed that there was a significantly
higher number of net-contralateral rotations in the 6-OHDA-injected animals when compared to the
Sham group (t = 5.561; p < 0.001; Figure 2A). Regarding motor performance, which was addressed by
the staircase test, we also observed motor deficits after 6-OHDA injections. Of note, when we assessed
the forelimb use and skilled motor function, 6-OHDA-injected animals were clearly affected when
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compared to the control group (Sham; F(1,25) = 222,82; p < 0.0001; η2partial = 0.899, Figure 2B). Finally,
by performing a forced-choice task (in which animals are forced to choose one of the steps-side), we
found a significant impairment on the affected side (left-side) when compared to the control group
(Sham; right side (FCR): t = 2.02, p = 0.0536; and left side (FCL) t = 10.93; p < 0.001, Figure 2C).
Figure 2. 6-OHDA PD model phenotypic validation. Using the apomorphine turning behavioral test,
it was verified that after 3 weeks of 6-OHDA injections, there was (A) an intense turning behavior
promoted by the injection of apomorphine when compared to Sham group, demonstrating that animals’
dopaminergic integrity was affected. Additionally, through the staircase test, it was verified that after
6-OHDA administration there was a (B,C) significant reduction on fine motor coordination of the tested
animals. For apomorphine turning behavioral test Sham n = 9, 6-OHDA n = 18. For staircase Sham
n = 9, 6-OHDA n = 18. Data presented as mean ± S.E.M. *** p < 0.001. FCR—forced choice task at right
side; FCL—forced choice task at left side.
3.2. hBM-MSCs Secretome Improves 6-OHDA PD Motor and Histological Deficits
To access the therapeutic effects of hBM-MSCs secretome and levodopa in 6-OHDA PD animals,
animal motor performance was assessed at 1 and 4 weeks through the staircase test. From the results,
statistical analysis revealed that after hBM-MSCs secretome administration, there was a significant
between-subjects effect (i.e., factor treatment: F(3,23) = 37.58; p < 0.001; η2partial = 0.831), also for the
within-subjects effect (i.e., factor time: F(2,46) = 3.99; p = 0.025; η2partial = 0.148), but no interaction
between these factors (F(6,46) = 1.27; p = 0.290; η2partial = 0.142). Comparing the hBM-MSCs secretome
injected animals with the untreated group (6-OHDA), post-hoc analysis revealed that the administration
of the secretome led to a significant amelioration of animal’s motor performance after 1 week (p = 0.036,
Figure 3A). Additionally, and concerning the forced-choice task procedure, animals injected with
hBM-MSCs secretome also had a significant motor amelioration. Statistical analysis revealed an
effect for the factor treatment (F(3,20) = 45.84; p < 0.001; η2partial = 0.873), also for the factor time
(F(2,40) = 18.58; p < 0.01; η2partial = 0.482) as well as interaction between these factors (F(6,40) = 3.11;
p = 0.013; η2partial = 0.318). Considering hBM-MSCs secretome effects, post-hoc testing revealed an
increased success rate of eaten pellets in the affected side comparing to the untreated group (6-OHDA,
left side, p = 0.046, Figure 3B; right side, p = 0.945, Figure 3C). Concerning levodopa, post-hoc analysis
revealed no differences when compared to the untreated group (6-OHDA; p = 0.742; Figure 3A), as
well as when compared to the hBM-MSCs secretome (p = 0.457; Figure 3A). The same observation was
also seen in the forced choice task both for the untreated group (6-OHDA; left side, p = 1.0 right side,
p = 1.0; Figure 3B,C) and hBM-MSCs secretome (left side, p = 0.995; right side, p = 1.0; Figure 3B,C).
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Figure 3. Impact of hBM-MSCs secretome and levodopa interventions on motor coordination
performance of 6-OHDA PD animals—staircase. (A) The paw reaching motor coordination performance
of the animals demonstrated a significant amelioration (at one week, p < 0.05) of the forelimb coordination
of the hBM-MSCs secretome-injected animals when compared to the untreated group 6-OHDA. Even
under a (B,C) paw reaching forced-task, the animals injected with hBM-MSCs secretome presented
a better performance (at one week after injection; p < 0.05) when compared to the untreated group
6-OHDA on the (B) (left) affected side (FCL). Such pieces of evidence, were, in turn, not observed in
the levodopa-treated animals when compared to the untreated group 6-OHDA (A–C). Sham n = 9,
6-OHDA n = 7, Levodopa n = 5, and hBM-MSCs secretome n = 6. Data presented as mean ± S.E.M.
*hBM-MSCs secretome-injected animals statistically different from 6-OHDA, p < 0.05; #Sham animals
statistically different from 6-OHDA, hBM-MSCs secretoma and levodopa-injected animals, *** p < 0.001.
FCR—forced choice task at right side; FCL—forced choice task at left side.
To further analyze the impact of 6-OHDA-induced DAn degeneration, as well as the resulting
hBM-MSCs secretome and levodopa interventions, we proceeded to histological analyses for TH
staining. From the results, we found that after 6-OHDA injections, there was a significant loss of DAn into
the SN (Figure 4B–D) when compared to the control group (Sham, Figure 4A). Notwithstanding, after
therapeutic intervention, statistical analysis revealed an effect for the factor treatment (F(3,18) = 153.70;
p < 0.001; η2partial = 0.962) in which the local administration of hBM-MSCs secretome potentiated the
survival of DAn, as a significant number of TH-positive cells was observed in the SN when compared to
the untreated group (p = 0.019, Figure 4E). In contrast, concerning levodopa administration, no effects
were observed when compared to the untreated group (p = 0.693), and to the treated with hBM-MSCs
secretome (p = 0.242; Figure 4E). The same trend was also observed for the TH-positive terminals in the
striatum (Figure 4G–I), which was assessed by densitometry analysis. Post-hoc analysis revealed an
effect for the factor treatment (F(3,18) = 348.76; p < 0.001; η2partial = 0.983; Figure 4J), demonstrating that
the administration of the hBM-MSCs secretome directly in the STR was able to enhance TH-positive
terminals when compared to the untreated group 6-OHDA (p = 0.01, Figure 4J). Nevertheless, such
significance was not observed when compared to levodopa (p = 0.304; Figure 4J). Concerning levodopa
treated animals per se, as it was observed for the SN, no significant effects were also observed for the
TH-positive terminals in the striatum when compared to those untreated (p = 0.090; Figure 4J).
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Figure 4. Striatum (STR) and Substantia nigra (SN) brain slices photomicrographs stained for Tyrosine
Hydroxylase (TH). Compared to the (A,F) Sham group, all the animals injected with 6-OHDA had a
significant reduction on the TH-positive staining both in the SN and STR. Notwithstanding, animals
treated with the (D,I) hBM-MSC secretome display a significant impact on STR and SN histological
deficit, with more TH-positive cells and fibers being observed when compared to (B,G) untreated group
6-OHDA (E,J). Concerning levodopa (C,H), although a slight increase was observed, no differences
were observed when compared to the untreated group 6-OHDA (B,G) and hBM-MSCs secretome (D,I)
both in the SN and STR (E,J), respectively. Data presented as mean ± S.E.M. Sham n = 9, 6-OHDA n = 7,
Levodopa n= 5, and hBM-MSCs secretome n = 6; * hBM-MSCs secretome-injected animals statistically
different from 6-OHDA, p < 0.05. #Sham animals statistically different from 6-OHDA, levodopa, and
hBM-MSCs secretome-treated animals, p < 0.001. Scale-bar: for SN 200 µm; for STR: 1 mm.
4. Discussion
Currently, it is widely accepted that the ability to modulate, slow, or preferably stop PD progression
is a major scientific and clinical need [25]. Such a gap could be explained by the multifactorial profile of
the disease (e.g., alpha-synuclein accumulation, mitochondrial and UPS dysfunction, oxidative stress,
and neuroinflammation), which leads to the extensive loss of DAn in the nigrostriatal pathway, thereby
resulting in debilitating motor limitations [2] In the in vivo experiments performed in the present study,
we used a classical PD rat model, induced by unilateral injection of 6-OHDA into the MFB [17,20]. As
previously shown by our group in similar experiments [16,26], the model was successfully validated,
by presenting impairments in the dopaminergic nigrostriatal integrity as shown in the rotameter
behavioral test (Figure 2A), with the animals displaying an intense turning behavior when compared
to the control group (Sham; injected with vehicle). Still, and by addressing fine motor coordination
of the 6-OHDA PD animals, such capability was also found to be significantly diminished, as the
animals presented deficits in skilled motor functions as evidenced by the staircase test, respectively
(Figure 2B,C).
Considering the effects of the treatment pipeline used, it should be highlighted that on the skilled
motor function (staircase), hBM-MSCs secretome was the only group found to increase the animals’
success rate of eaten pellets, when compared to control (untreated) animals (6-OHDA; Figure 2A).
Additionally, in the forced-choice task and after one week as well, hBM-MSC secretome has potentiated
(in the affected side) the paw reaching motor performance of 6-OHDA PD animals when compared
to the untreated group (Figure 2B). Moreover, we have also observed that hBM-MSCs secretome
administration increased TH-positive neurons and fibers both in the SN and STR (Figure 4), thereby
reinforcing the positive skilled motor function amelioration observed (Figure 3). These outcomes
nicely correlate with our previous results, demonstrating that stem cells secretome may start being
considered a potentially active component in PD modeling and repair [16,26].
Cells 2020, 9, 315 9 of 18
Taking advantage of the proteomic databases previously generated by our group [15,16,27],
and in order to further explore possible underlying mechanisms behind the secretome effects, by
using the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) bioinformatics tool,
we found a (PD) protein association network composed by 21 proteins, namely Thioredoxin-1
(Trx1/TXN), Semaphorin-7A (SEMA7A), Ubiquitin carboxy-terminal hydrolase L1 (UCHL1), Pigment
epithelium-derived factor (PEDF/SERPINF1), Brain-derived neurotrophic factor (BDNF), Clusterin
(CLU), Stromal cell-derived factor 1 (SDF-1/CXCL12), Cyclophilin A (CypA/PPIA), Cyclophilin B
(CypB/PPIB), Cystatin C (Cys C/CST3), Vascular endothelial growth factor (VEGF), Protein Deglycase
DJ-1 (PARK7), Galectin 1 (Gal-1/LGALS1), Glial cell line-derived neurotrophic factor (GDNF),
Cadherin 2 (CDH2), Interleukin 6 (IL-6), Heat shock protein 27 (HSP27/HSPB1), Peroxiredoxin 1
(PRDX1), Ubiquitin-protein ligase 3A (UBE3A), Metalloproteinase 2 (MMP-2), and glial-derived nexin
(GDN/SERPINE2)—Figure 5. From this association network, we found a cluster of 13 proteins directly
interconnected, which from the biological processes (Figure 5A) and molecular function (Figure 5B)
were found to have important actions having in mind the dopaminergic system and PD.
Figure 5. hBM-MSCs are producers of neuroregulatory molecules impacting PD. From previously
generated proteomic databases derived from Bioplex-Luminex and Mass Spectrometry-based analysis,
we were able to identify the presence of several (neuro)trophic factors and cytokines with important
roles and therapeutic actions on PD. Of note, by STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins) bioinformatics research tool analysis, from those databases we identified a cluster
of 21 interconnected proteins, namely Trx1 (TXN), SEMA7A, UCHL1, PEDF (SERPINF1), BDNF,
Clusterin (CLU), SDF-1 (CXCL12), CypA (PPIA), CypB (PPIB), Cys C (CST3), VEGF, DJ-1 (PARK7),
Gal-1 (LGALS1), GDNF, CDH2, IL-6, HSP27 (HSPB1), PRDX1, UBE3A, MMP-2, and GDN (SERPINE2),
which from the (A) biological processes and (B) molecular function analysis revealed important actions
to PD modeling and repair.
Accordingly, and regarding Trx1, it plays a vital role in the maintenance of a reduced intracellular
redox state, and together with glutathione dismutase, Trx1 has been described as an important
antioxidant agent leading to the protection of neuronal cells as DAn, by regulating the detrimental
effects of oxidative stress and ROS formation [28]. Still, in vitro studies showed Trx1 as a regulator of
apoptosis, demonstrating a modeling function on the activity of certain proteins such as the apoptosis
signal-regulating kinase-1 (ASK-1) [29], thereby protecting DAn from dopamine-induced cell death
(when exposed to 6-OHDA) due to its capability to reduce the neurotoxic dopamine metabolites, such
as 6-OHDA-quinone [29]. Additionally, in an MPTP PD model, Trx1 was found to be an inducer of DAn
cell survival, through the suppression of the endoplasmatic reticulum (ER) stress [30]. Nevertheless,
although elucidation of the specific function of Trx1 on PD is required, human postmortem PD
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brains demonstrated that the levels of Trx1 were found to be significantly decreased, indicating
that Trx1 secretion and function could be helpful for the study of new pathways and targets for
PD repair [31]. Semaphorins, as SEMA7A, are secreted and transmembrane molecules that bind to
plexin/neuropilin or integrin receptors, being involved in paracrine axonal guidance and development
of functional neuronal networking [32,33]. Pacelli and colleagues [34] have described SEMA7A as a
modulator of ROS-mediated neurodegeneration, by demonstrating that SEMA7A can reduce DAn
axonal arborization and vulnerability through its capability to the decrease mitochondrial oxygen
demanding and ROS production. Concerning UHCL1, ubiquitin plays a crucial role in the maintenance
of the ubiquitin-proteasome system (UPS), which has been suggested as being involved in the initiation
and progression of PD [35,36]. In fact, in PD brain tissue, UCHL1 is present in Lewy bodies, displaying
an import role in maintaining UPS pool and DAn cell survival [36]. Nevertheless, although UCHL1
is involved in a genetic form of PD [37], its functions in (normal physiological conditions) living
cells and tissues are still poorly understood, with several studies assuming UCHL-1 dysfunction
associated to ubiquitinated proteins accumulation, as alpha-synuclein, the major cause of DAn cell
degeneration [38,39]. Additionally, positive roles of UCHL1 in many other biological processes have
also been claimed such as cell signaling, cell cycle, DNA repair, and other ubiquitination-dependent
biological processes, which could represent additional routes for the establishment of therapeutic
targets for the treatment of PD [38].
PEDF was previously described by our group as an important PD neurotrophic and neuroprotective
molecule [16]. Such properties were tested and demonstrated by Falk and colleagues [40] who, by
comparing PEDF with other PD therapeutic molecules (as GDNF), showed that PEDF has advantages
in the ease of delivery and amelioration of functional outcomes. Similar results were then shown by
Yasuda and colleagues [41] that demonstrated that PEDF levels increase in response to acute insults
on the dopaminergic system, by correlating this response to the capacity of PEDF to interact and
stimulate the activation of the NF-kB signaling cascade, which is involved in the modulation and
expression of critical factors to DAn cell survival, namely BDNF and GDNF [40]. Regarding BDNF,
studies have been described as a credible protective molecule in the degenerative process of PD,
being an important molecule for the development, maturation, repair, and plasticity of DAn [42,43].
It has been demonstrated that the genetic inhibition of BDNF expression was correlated with a
loss of nigral DAn [43], thereby indicating its importance in DAn cell survival/viability and neurite
outgrowth as well [44]. Such pieces of evidence reinforce the importance of BDNF in PD initiation
and progression, as it was defended that a decrease of BDNF expression in the SN might be one
of the earlier steps at the onset of PD, by increasing DAn cells sensitization [45]. Regarding SDF-1,
this factor is being positively correlated with beneficial effects on PD, being described as a promoter
of DAn migration and neuritogenesis, which may constitute an interesting tool in PD regenerative
medicine to improve (re)innervation of the nigrostriatal pathway [46]. Indeed, several studies have
already highlighted that in addition to DAn migration, SDF-1 has an active role in the regulation
of axonal pathfinding and elongation, thereby being considered a modulator of the dopaminergic
system and functionality [46,47]. Looking to CypA, although the therapeutic effect of this protein
under the PD context remains to be explored, few studies have indicated a potential role of it in
the modulation of the ASK1 signaling pathway in oxidative stress-induced apoptosis through the
inhibition of JNK and p38 activities [48,49]. Regarding Cys C, this protein has been largely explored as
a promising therapeutic molecule under the context of Alzheimer’s disease, acting as a multitasking
player in the induction of cellular autophagy, or via the inhibition of amyloid-β (Aβ) aggregation,
leading to brain damage prevention [50,51]. Under the context of PD, only a few studies have already
addressed the potential impact of Cys C [52,53]. For instance, Jing and colleagues [52] have recently
demonstrated in A53T SNCA (alpha-synuclein overexpression model) transgenic mice that Cys C
is involved in the neuroprotection of DAn, through a mechanism involving the upregulation of
VEGF and NURR1 and the downregulation of Ser129-phosphorylated SNCA. Still, these authors
also found that this neuroprotective effect could also be explained by the active role of Cys C in
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autophagy, as demonstrated by the upregulated levels of LCB3 in Cys C-treated animals. Similar
outcomes were previously presented by Xu and colleagues [53], who found Cys C as a survival
promoter of DAn after 6-OHDA insult both in vitro and in vivo, suggesting that Cys C may play
an important role in brain self-protection following injury. Concerning VEGF, and it was already
mentioned, this factor plays an important role in the neurorescuing of DAn, by interacting with
different players in the potentiation of the dopaminergic system [52,54]. Similarly, it is DJ-1 that has
been described as a major player and target for PD modeling and repair [2,55,56]. Notably, studies have
demonstrated that DJ-1 deficiency sensitizes microglial cells to release pro-inflammatory cytokines
(e.g. IFN-γ and I- TAC), causing inflammatory damage to DAn, thereby indicating that DJ-1 could
be a potential key molecule to tackle PD [57]. Besides, DJ-1 was also found to be a modulator of
mitochondrial function [58]. Chen and colleagues [58], have recently shown that DJ-1 can directly
bind to the F1FO ATP synthase β subunit, decreasing mitochondrial uncoupling and enhancing
ATP production efficiency, correlating such outcomes with an enhancement of dopaminergic cell
metabolism and growth [58]. Interestingly, in addition to these anti-inflammatory and mitochondrial
functional effects, DJ-1 has also been described as a PD antioxidant agent, by regulating specific
transcription factors involved in the increase of the Trx and GSH redox systems, which in turn can also
modulate DJ-1 functionality [56,59]. GDNF, in contrast, is a well-established neurotrophic agent for
DAn survival, viability, and functionality both in vitro and in vivo, by maintaining its morphology
and neurochemical phenotype [60]. From the application point of view, and given, for instance, prior
6-OHDA administration, GDNF demonstrated to be effective in the protection of striatal DAn [61].
In addition to neuroprotection, GDNF has also been found as a modulator of apoptosis, by presenting
an active role in upregulating anti-apoptotic proteins such as Bcl2 and Bcl-X through PI3K signaling
pathway [42,60,62]. Still, GDNF has also been described as an inducer of antioxidant activities, as it
was found to be able to positively increase the activity superoxide dismutase, catalase, and glutathione
peroxidase, allowing the detoxification of ROS-induced degeneration [63]. Even under clinical trials,
GDNF has presented promising results, although more studies should be explored to further address
its full potentiality [64]. Following GDNF effects, it was interesting to find a connection with CDH2,
which according with Zuo and colleagues [65] appears to be a mediator and an effector of GDNF
actions in the activation of the PI3k/Akt signaling pathway, which has been correlated with protective
effects on DAn. Indeed, the same authors also demonstrated that when they knocked down CHD2,
the protective effects of GDNF was diminished, hypothesizing that CDH2 is linked to the biological
effects of GDNF in DAn [65]. In line with this, Sakane and Miyamoto [66] demonstrated that CDH2
has also important functions in DAn differentiation, by demonstrating that it regulates Wnt-b-catenin
signaling and controls the proliferation and differentiation processes of DAn progenitors in the ventral
midbrain region. Regarding IL-6, studies have shown that its presence in MSCs secretome plays
important roles in scavenging ROS, as superoxide radicals, by increasing the antioxidant enzyme
activity, through STAT pathways, and leading to DAn protection [67]. In addition to this antioxidant
activity, IL-6 has also been linked to DAn neuroprotection [68]. Indeed, studies have demonstrated
that knocking down IL-6 increases the vulnerability of DAn to MPTP, by speculating that IL-6 is
capable of protecting DAn from the MPP+-induced toxicity [69,70]. Considering Hsp27, Lee and
colleagues [71] have described this molecule as a protective agent of DAn, due to its capability to
attenuate alpha-synuclein-induced toxicity. In line with this, Cox and colleagues [72] demonstrated
that Hsp27 can directly bind to alpha-synuclein fibrils, thereby preventing or disrupting the onset
and progression of its aggregation and consequent debilitating effects on DAn. Concerning PRDX1, it
has been presented as a potent antioxidant agent, promoting DAn cell survival and protection from
toxic insults as 6-OHDA, respectively [73]. The modulation of p38-MAPK and caspase-3 signaling
pathways is being defined as the molecular mechanism by which PRDX1 exerts a protective role in
experimental models of PD, further supporting it as an important regulator of the (DAn) cell death
pathway [73,74]. Finally, GDN is being described as an interesting molecule playing crucial roles
in the enhancement of neurite outgrowth and neuroprotection through the prevention of oxidative
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stress [75,76]. Nevertheless, although Clusterin, CypB, Gal-1, UBE3A, and MMP-2 were not found to
be directly interconnected, its presence on MSCs secretome has also been correlated with positive and
promising effects on PD modeling and repair, namely through the modulation of oxidative stress and
neuroinflammation, mitochondrial dysfunction prevention, and alpha-synuclein degradation, thereby
exerting neuroprotective properties in PD-related environments [77–81].
Considering levodopa effects, such pieces of evidence (as seen in hBM-MSCs secretome application)
were not, in contrast, observed in the treated animals. In fact, the pharmacological application of
levodopa (even being the standard treatment of PD) remains still controversial, due to an inconsistency
of results regarding its truly mechanistic effects [82]. Of note, while in vitro studies have demonstrated
both toxic (through dopamine metabolism and autoxidation, giving rise to quinones and hydrogen
peroxide) and protective effects (at certain concentrations) of levodopa on DAn, in vivo and even
clinical studies have not provided yet any convincing data [82]. Inevitably, levodopa dose-regiment
is, indeed, a critical issue in treating PD [83,84]. Colamartino and colleagues [82] have hypothesized
that one of the most difficult aspects of experimental analysis regarding levodopa treatment is related
to the individual response of each subject, both regarding the effectiveness of therapy and its side
effects. Additionally, it has also been defended that this discrepancy of results could, most likely, be
due to the intrinsic nature of the molecule of levodopa, which has both pro-oxidant and antioxidant
properties that depend on the concentrations used [85]. Preclinical studies have demonstrated that
while acute treatments with levodopa (as used in the present study) might not be able to restore motor
activity, chronic administration appears to be more effective in reducing parkinsonian motor deficits
and in restoring striatal synaptic functionality [86]. However, this therapeutic efficacy of levodopa
is just remarkable in the first years of treatment if a conceivable presence (in sufficient number) of
spared DAn exists, which allows the conversion of levodopa and mediate the physiological release
of dopamine [87]. Notwithstanding, as PD progresses, the responsiveness to levodopa declines over
time, thereby requiring an increase in dosage, which in the majority of the cases is coincident with a
more rapid reduction in levodopa efficacy at the end of dose, known as the ‘off-phase’ [88], which
could explain the poor performance of our levodopa-treated animals (Figure 3). Therefore, despite
its longevity, it becomes clear that understanding the mechanism underlying both therapeutic and
negatives effects of levodopa is critical [89], as it could open new questions and hypotheses about
alternative pathways for better understanding the etiology and pathophysiology of PD [90].
In conclusion, the present findings support hBM-MSCs secretome administration as a potential
therapeutic tool in treating PD. Although we suggest candidate molecules and possible mechanisms of
hBM-MSCs secretome-mediated effects, further detailed studies are needed to carefully and clearly
define which players may be responsible for its therapeutic actions. Still, although no significant
differences were observed for levodopa, additional work is necessary to improve the applicability of
this approach. For instance, the route of administration of hBM-MSCs secretome should be revised. Of
note, instead of intracranial injections (which is an invasive protocol from the clinical point of view),
intravenous injections should be considered, which could represent a more reliable way to make a
‘direct’ comparison with levodopa administration. Still, as to date, no regenerative/neuroprotective
strategy was already approved as a PD therapy [91], a fact that can be partially attributed to the
‘one-disease-one-target’ view that has been followed [92], the development of combinatorial strategies
may overcome the limitations of single drug approaches, particularly by combining the latter (as
levodopa) with stem cells secretome. By doing so, it will be reasonable to presume that potential
treatments than can, per se, or in combination modulate or slow PD progression will be the result of a
better understanding of PD pathophysiology.
5. Conclusions
Re-establishing DA level equilibrium, nigrostriatal function and integrity and, with it, regaining
the loss of sensory-motor functionality is one of the main challenges of PD regenerative medicine.
By comparing hBM-MSC secretome and levodopa applications independently, although no differences
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were observed between them, we observed a significant amelioration in the animal behavior and (DAn)
histological densities of secretome-treated animals when compared to those untreated (6-OHDA).
Although the underlying mode-of-action of hBM-MSCs secretome remains unexplored, we hypothesize
it as a multitargeted modulator of different neural mechanisms triggered by presence of multifactorial
proteic composition such as Trx1, SEMA7A, UCHL1, PEDF, BDNF, Clusterin, SDF-1, CypA, CypB, Cys
C, VEGF, DJ-1, Gal-1, GDNF, CDH2, IL-6, HSP27, PRDX1, UBE3A, MMP-2, and GDN, respectively.
Therefore, our findings suggest that the stimulation of PD histological and behavioral deficits promoted
by the secretome appears to not be dependent on the presence of one secreted factor, but from an
integrated interaction of several, allowing the gaining of new insights concerning the potential interplay
of these soluble factors and their neuroprotective, antioxidant, anti-apoptotic, and DAn homeostatic
effects, which may lead to a rational design of new therapeutic or adjuvant strategies for the functional
recovery of PD.
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